The present invention relates to complex particles using methylene blue for treating a skin disease caused by Propionibacterium acnes or Staphylococcus aureus and a composition for treatment including the complex particles. The complex particles in the present invention can be used as a photosensitizer for a photodynamic therapy and complex particles having a micelle form in which hydrophilic methylene blue and two hydrophobic organic acids are combined, and as a result, pore penetration is easy and an occlusion time can be significantly reduced to 30 minutes as compared with conventional phototherapy requiring an occlusion time of 1 hour to 3 hours. Further, in order to reduce side effects of a residual photosensitizer in phototherapy using an existing photosensitizer due to photoreaction and photobleaching of the methylene blue-organic acid complex, a light protection (light blocking or light shielding) time when contact of light needs to be avoided for 24 hours or more after treatment can be significantly reduced to 3 hours, and target treatment for Propionibacterium acnes, Staphylococcus aureus, or the like which is a cause of acne is possible.

Various exemplary photoreactions can be provided, including reactions generally based on triplet-triplet annihilation upconversion. Representative photosensitizers include PdPc(OBu)8 and PtTPTNP. Representative annihilators include FDPP and TTBP. Such exemplary photoreactions, systems and methods may be used in a variety of applications, including various biological or physical applications. Exemplary methods can also be provided for making or using such systems, photoreactions, kits including such systems, or the like.

The present document describes methods and uses of compositions which comprise at least one photoactivator or chromophore in association with a pharmacologically acceptable carrier for use in reducing pain that is associated with a medical condition in a subject.

Methods and systems for performing optogenetics using X-rays or ultrasound waves are provided. Visible-light-emitting nanophosphors can be provided to a sample, and X-ray stimulation can be used to stimulate the nanophosphors to emit visible light. Alternatively, ultrasonic waves can be provided to the sample to cause sonoluminescence, also resulting in emission of visible light, and this can be aided by the use of a chemiluminescent agent present in the sample. The emitted light can trigger changes in proteins that modulate membrane potentials in neuronal cells.

A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier. A system for treating a disease in a subject in need thereof includes a) the above-noted suspension, b) a photoactivatable drug containing 8-methoxypsoralen (8-MOP or UVADEX) untethered from the two or more phosphors, c) one or more devices which infuse the photoactivatable drug and the suspension including the pharmaceutically acceptable carrier into a diseased site in the subject, and d) an x-ray source which is controlled to deliver a dose of x-rays to the subject for production of the ultraviolet light.

An upconversion nanoparticle includes at least one host selected from LiYF.sub.4, NaY, NaYF.sub.4, NaGdF.sub.4, and CaF.sub.3, at least one sensitizer selected from Sm.sup.3+, Nd.sup.3+, Dy.sup.3+, Ho.sup.3+, and Yb.sup.3+ doped in the at least one host, and at least one activator selected from Er.sup.3+, Ho.sup.3+, Tm.sup.3+, and Eu.sup.3+ doped in the at least one host. The upconversion nanoparticle is designed using a calculation from first principles to absorb light in the near-infrared wavelength range whose stability is ensured. Further, a hyaluronic acid-upconversion nanoparticle conjugate, in which the upconversion nanoparticle as described above is bonded to hyaluronic acid, is provided to be used in various internal sites with a hyaluronic acid receptor, particularly enables targeting, and increases an internal retention period and biocompatibility thereof.

Methods and systems for performing optogenetics using X-rays or ultrasound waves are provided. Visible-light-emitting nanophosphors can be provided to a sample, and X-ray stimulation can be used to stimulate the nanophosphors to emit visible light. Alternatively, ultrasonic waves can be provided to the sample to cause sonoluminescence, also resulting in emission of visible light, and this can be aided by the use of a chemiluminescent agent present in the sample. The emitted light can trigger changes in proteins that modulate membrane potentials in neuronal cells.

A liquid crystal nanoparticle (LCNP)-based system allows for the encapsulation and targeted delivery of Zinc (II) phthalocyanine (ZnPC) to the plasma membrane bilayer of living cells for photodynamic therapy (PDT). The formulation comprises LCNPs that are loaded in their hydrophobic core with perylene (PY) and ZnPC. In embodiments, the LCNP surface is functionalized with Poly(ethylene glycol)-cholesterol conjugates (PEG-Chol) and/or another material enabling targeting the particle to the cellular membrane. This can improve cell killing via reactive oxygen species (ROS) generation as it allows for the localized ROS-mediated peroxidation of lipids in the membrane bilayer.

Photodynamic therapy systems comprising a nanoparticle that emits electromagnetic radiation having a first wavelength when irradiated with electromagnetic radiation, a photosensitizer which absorbs electromagnetic radiation of said first wavelength and a biocompatible mesoporous material are disclosed herein. In some examples, the photodynamic therapy system comprises a core comprising the nanoparticle, a first shell comprising the biocompatible mesoporous material, and a photosensitizer embedded in the first shell. Upon irradiation by, for example, X-rays, the nanoparticle can function as a transducer, converting X-ray photons to visible photons, and in turn, activating the photosensitizers. Methods of using the photodynamic therapy system are also disclosed.

The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.